Skip to content

    Cipla

    CIPLANeutral
    Healthcare·13 May 2025
    Management Summary

    FY25 marked a year of historic achievements for Cipla with multiple business milestones across geographies. The company demonstrated operational excellence through successful FDA inspections while building a robust pipeline for future growth.

    Highlights

    7

    • One India business surpassed landmark of INR 11,000 crores revenue

    • North America achieved all-time high annual revenue of $934 million

    • Foracort became first brand in IPM history to cross INR 900 crores

    • Five manufacturing facilities classified as VAI by US FDA

    • Annual revenue of INR 27,548 crores with 8% YoY growth

    • EBITDA margin of 25.9% for FY25, exceeding guidance

    • Strong pipeline progress with respiratory and peptide assets

    What Changed4

    vs Q1 FY26

    Tone shiftcautiously optimistic with clear recovery roadmap → highly confident and achievement-focusedGuidance items5 → 2 (-3)Risks discussed5 → 2 (-3)Q&A highlights5 → 3 (-2)
    Key financials

    Metrics

    9

    Periods

    2

    Headline

    6
    • Annual Revenue
      ₹27,548 Cr
      YoY+8%
    • Annual EBITDA Margin
      25.9%
      YoY+1.4%
    • Annual PAT
      ₹5,273 Cr
      YoY0%
    • Annual R&D Investment
      ₹1,524 Cr
      YoY0%
    • One India Revenue
      ₹11,000 Cr
      YoY+7.0%

    Q4

    3
    • Revenue
      ₹6,730 Cr
      YoY+9%
    • EBITDA Margin
      22.8%
      YoY0%
    • PAT
      ₹1,222 Cr
      YoY0%

    Guidance & targets

    2
    CategoryTargetPriority
    US Peptide Launches
    Product Launches
    2 to 3 peptide assets
    		High
    Pipeline Development
    Asset Filings
    10 more peptides and complex generics
    		High

    Risks & concerns

    2
    RiskSeverity

    Seasonal Market Challenges

    Growth realized despite seasonal challenges in acute category, showing derisked business mix — Other acknowledged

    medium

    Regulatory Timeline Dependencies

    Multiple assets filed and pending approval, launches dependent on regulatory timelines — Other acknowledged

    medium

    Q&A highlights

    3

    “Foracort, our leading inhalation brand became the first brand in the history of IPM to cross INR900 crores”

    Historic milestone demonstrating market leadership in respiratory segment

    asked by Management Commentary

    1 min read4 chapters

    Detailed Narrative

    01

    Historic Revenue Milestones

    FY25 marked multiple historic achievements with One India business crossing INR 11,000 crores and North America achieving all-time high annual revenue of $934 million. Foracort became the first brand in IPM history to exceed INR 900 crores.

    02

    Operational Excellence Validated

    US FDA inspected five Indian manufacturing facilities (Patalganga, Kurkumbh, Goa, Virgonagar, and Medispray), all classified as VAI, demonstrating commitment to quality and compliance standards.

    03

    Portfolio Expansion Strategy

    Strategic partnerships with global players including collaborations with Orchid Pharma, Takeda, and Formosa. Added 4 brands to the INR 100+ crores club, bringing total to 26 brands.

    04

    Strong Pipeline Development

    Robust US pipeline with 6 respiratory assets filed including Symbicort and Qvar, 9 peptide and complex generic assets filed, with commitment to launch 2-3 peptide assets in FY26.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.